
What smart money is saying about Sanuwave Health
4 funds in our archive have pitched Sanuwave Health — most recently Cedar Grove in March 2026.
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Fund coverage · 4 theses
- Cedar GroveMarch 2026
Sanuwave Health offers an ultrasound wound-care device poised to benefit from CMS policy shifts, a refinancing, and a long runway.
Read the full thesis - Deep Sail CapitalDecember 2025
Sanuwave Health, Inc. is a specialty medical device company leveraging a high-margin recurring model, strong IP and leadership, and favorable reimbursement tailwinds to drive multi-year growth at an attractive valuation.
Read the full thesis - Infuse AMDecember 2025
Sanuwave sells a razor-and-blades UltraMist wound-care device, is led by a capital-allocation savvy CEO, and offers >30% growth with improved debt terms at a reasonable ~18x forward EBIT.
Read the full thesis - SRK CapitalSeptember 2025
Sanuwave Health, Inc. is experiencing rapid growth with a 51% revenue increase, a new national sales force, and an imminent Nasdaq uplisting, making its shares an attractive investment opportunity.
Read the full thesis
Read every full thesis on Sanuwave Health
Unlock all 4 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→